BR112014014674A2 - angiotensinas para tratamento de fibrose - Google Patents
angiotensinas para tratamento de fibroseInfo
- Publication number
- BR112014014674A2 BR112014014674A2 BR112014014674A BR112014014674A BR112014014674A2 BR 112014014674 A2 BR112014014674 A2 BR 112014014674A2 BR 112014014674 A BR112014014674 A BR 112014014674A BR 112014014674 A BR112014014674 A BR 112014014674A BR 112014014674 A2 BR112014014674 A2 BR 112014014674A2
- Authority
- BR
- Brazil
- Prior art keywords
- fibrosis
- treatment
- angiotensins
- prevention
- compositions
- Prior art date
Links
- 108010064733 Angiotensins Proteins 0.000 title abstract 2
- 102000015427 Angiotensins Human genes 0.000 title abstract 2
- 206010016654 Fibrosis Diseases 0.000 title abstract 2
- 239000002416 angiotensin derivative Substances 0.000 title abstract 2
- 230000004761 fibrosis Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 abstract 1
- 206010060932 Postoperative adhesion Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 108010021281 angiotensin I (1-7) Proteins 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 201000002793 renal fibrosis Diseases 0.000 abstract 1
- 230000037390 scarring Effects 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Reinforced Plastic Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576673P | 2011-12-16 | 2011-12-16 | |
| US201161579936P | 2011-12-23 | 2011-12-23 | |
| PCT/US2012/069930 WO2013090833A1 (en) | 2011-12-16 | 2012-12-14 | Angiotensins for treatment of fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014014674A2 true BR112014014674A2 (pt) | 2017-06-13 |
Family
ID=48613248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014014674A BR112014014674A2 (pt) | 2011-12-16 | 2012-12-14 | angiotensinas para tratamento de fibrose |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20150057216A1 (https=) |
| EP (1) | EP2790716A4 (https=) |
| JP (1) | JP2015504870A (https=) |
| KR (1) | KR20150028761A (https=) |
| CN (1) | CN104302305A (https=) |
| AU (1) | AU2012351939A1 (https=) |
| BR (1) | BR112014014674A2 (https=) |
| CA (1) | CA2859573A1 (https=) |
| WO (1) | WO2013090833A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007079139A2 (en) | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| RU2015147241A (ru) * | 2013-05-24 | 2017-06-29 | Терикс Фармасьютикалз Лтд. | Пептиды ангиотензина при лечении синдрома марфана и связанных с ним нарушений |
| JP6254692B2 (ja) * | 2013-07-03 | 2017-12-27 | ジ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ | 認知機能不全を治療するための方法 |
| AU2015258997B2 (en) * | 2014-05-16 | 2019-04-18 | Ultrast, Inc. | Phase-shifting formulations |
| JP6666899B2 (ja) | 2014-07-21 | 2020-03-18 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ | Ａｎｇ−（１−７）誘導体オリゴペプチド、ならびにそれを使用および作製するための方法 |
| US10183055B2 (en) | 2014-07-21 | 2019-01-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications |
| KR20170063954A (ko) | 2014-10-07 | 2017-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정 |
| MA41120A (fr) * | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| JP2018527330A (ja) | 2015-07-30 | 2018-09-20 | モナシュ ユニバーシティー | 線維症の処置 |
| WO2017066552A1 (en) | 2015-10-14 | 2017-04-20 | Tarix Pharmaceuticals Ltd. | Methods and compositions for the treatment of epidermolysis bullosa |
| WO2017218623A1 (en) * | 2016-06-14 | 2017-12-21 | Tarix Orphan Llc | Methods and compositions for the treatment of epidermolysis bullosa |
| WO2019014710A1 (en) * | 2017-07-17 | 2019-01-24 | Monash University | ANGIOTENSIN RECEPTOR AGONISTS AND USES THEREOF |
| GB201913603D0 (en) | 2019-09-20 | 2019-11-06 | Vicore Pharma Ab | New compounds |
| WO2021164723A1 (en) * | 2020-02-20 | 2021-08-26 | Lee Sheau Long | Ginsenoside m1 as a modulator of angiotensin regulating enzymes and its use for treating diseases or conditions including symptoms caused by coronavirus |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| EP4085921A1 (en) * | 2021-05-04 | 2022-11-09 | CU-Pharmaceuticals UG | Angiotensin-(1-7) in the treatment of sars-cov related diseases |
| EP4085896A1 (en) * | 2021-05-04 | 2022-11-09 | CU-Pharmaceuticals UG | Pharmaceutical angiotensin-(1-7) compositions in the treatment of (sars)-cov- or (sars)-cov-2-infection related diseases |
| CA3249539A1 (en) | 2022-02-10 | 2023-08-17 | Vicore Pharma Ab | USE OF BULOXIBUTID FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS |
| GB202201723D0 (en) | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
| WO2025050228A1 (es) * | 2023-09-08 | 2025-03-13 | Pontificia Universidad Católica De Chile | Composición farmacéutica que comprende un péptido o una combinación de péptidos agonistas de los receptores mas, at1 y at2 |
| KR102743940B1 (ko) | 2023-10-06 | 2024-12-19 | 엠브릭스 주식회사 | 안지오텐신 전환효소 2 및 Fc 절편을 포함하는 나노디스크 및 이의 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69824445T2 (de) * | 1997-12-12 | 2005-06-30 | University Of Southern California, Los Angeles | Zusammensetzungen zur wundheilung |
| YU78601A (sh) * | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
| US7064127B2 (en) * | 2003-12-19 | 2006-06-20 | Mount Sinai School Of Medicine Of New York University | Treatment of hepatic fibrosis with imatinib mesylate |
| EP2163259B1 (en) * | 2008-09-12 | 2012-06-13 | Charité-Universitätsmedizin Berlin (Charité) | Use of an Ang-(1-7) receptor agonist in acute lung injury |
-
2012
- 2012-12-14 CN CN201280069856.3A patent/CN104302305A/zh active Pending
- 2012-12-14 JP JP2014547526A patent/JP2015504870A/ja active Pending
- 2012-12-14 WO PCT/US2012/069930 patent/WO2013090833A1/en not_active Ceased
- 2012-12-14 CA CA2859573A patent/CA2859573A1/en not_active Abandoned
- 2012-12-14 US US14/365,565 patent/US20150057216A1/en not_active Abandoned
- 2012-12-14 AU AU2012351939A patent/AU2012351939A1/en not_active Abandoned
- 2012-12-14 KR KR20147019878A patent/KR20150028761A/ko not_active Withdrawn
- 2012-12-14 BR BR112014014674A patent/BR112014014674A2/pt not_active Application Discontinuation
- 2012-12-14 EP EP12857486.0A patent/EP2790716A4/en not_active Withdrawn
-
2015
- 2015-11-23 US US14/948,985 patent/US20160074466A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2790716A1 (en) | 2014-10-22 |
| KR20150028761A (ko) | 2015-03-16 |
| WO2013090833A1 (en) | 2013-06-20 |
| US20150057216A1 (en) | 2015-02-26 |
| EP2790716A4 (en) | 2015-06-10 |
| WO2013090833A8 (en) | 2014-07-17 |
| CN104302305A (zh) | 2015-01-21 |
| US20160074466A1 (en) | 2016-03-17 |
| CA2859573A1 (en) | 2013-06-20 |
| JP2015504870A (ja) | 2015-02-16 |
| AU2012351939A1 (en) | 2014-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014014674A2 (pt) | angiotensinas para tratamento de fibrose | |
| WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
| BR112015009913A8 (pt) | composições farmacêuticas para o tratamento de doenças mediadas por cftr | |
| JP2014515038A5 (https=) | ||
| WO2012174487A8 (en) | Bromodomain inhibitors and uses thereof | |
| WO2012151512A3 (en) | Bromodomain inhibitors and uses thereof | |
| HK1211475A1 (en) | Combination therapy | |
| MX2018000688A (es) | Triciclicos sustituidos y metodo para usarlos. | |
| ECSP14013173A (es) | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida | |
| HK1224296A1 (zh) | 布罗莫结构域抑制剂 | |
| NZ709197A (en) | 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds | |
| WO2012075383A3 (en) | Bromodomain inhibitors and uses thereof | |
| CY1119007T1 (el) | Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης | |
| BR112015001847A8 (pt) | Composições e tratamento para doenças e distúrbios nos olhos | |
| WO2014153100A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| CL2011001977A1 (es) | Compuestos derivados de triazolopiridina, inhibidores de proteinas cinasas activadas por mitogeno p38; composicion farmaceutica; y su uso para el tratamiento de neumonia eosinofilica cronica, asma, enfermedad pulmonar obstructiva cronica y sindrome de angustia respiratoria en adultos, entre otras enfermedades. | |
| WO2009087212A3 (en) | Pyridine derivatives | |
| WO2014153235A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| BR112018007145A2 (pt) | ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso | |
| BR112015018071A2 (pt) | estra-1,3,5(10),16-tetraeno-3-carboxamidas | |
| WO2012162439A3 (en) | Compositions comprising fusidic acid and packages therefor | |
| EA201391481A1 (ru) | Аналоги эпоксиэйкозатриеновой кислоты и способы их получения и использования | |
| MX383583B (es) | Composiciones organicas para tratar enfermedades relacionadas con beta-enac. | |
| WO2015025226A3 (en) | Compositions and therapeutic methods for accelerated plaque regression | |
| BR112014015421A2 (pt) | alfa-amilases variantes e métodos de uso das mesmas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |